ReviewBiomedicines2026
A Review of the Potential Therapeutic Benefits of Quercetin for Uterine-Related Conditions.
Review in Biomedicines, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Quercetin is a naturally occurring flavonoid found in fruits, vegetables, and teas that is widely available as a dietary supplement. Numerous studies have investigated quercetin's therapeutic potential across a broad range of diseases and conditions. Collectively, these studies reveal its anti-inflammatory, antioxidant, anti-proliferative, anti-cancer, anti-fibrotic, antibacterial, endocrine-modulating, and senolytic properties, establishing quercetin as a polypharmacologic agent with diverse biological activities. This review describes quercetin's biochemical properties, bioavailability, and proposed mechanisms of action. It highlights the unique characteristics of the human uterus vs. other species and evaluates published evidence from pre-clinical and clinical studies supporting quercetin's pleiotropic effects and potential therapeutic benefits for six uterine-related conditions: endometrial cancer, endometriosis, adenomyosis, uterine infections, uterine fibroids, and polycystic ovary syndrome (PCOS). The findings support that quercetin targets multiple endometrial and other uterine cell types and may attenuate key pathological processes relevant to uterine disease. However, robust human clinical evidence supporting quercetin's efficacy is generally lacking. Critical knowledge gaps and translational barriers to advancing quercetin from a 'promising preclinical candidate' into an 'evidence-based therapeutic' for improving uterine health are discussed.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.